Vytorin and Zetia have been linked to serious, life-threatening side effects including myalgia, rhabdomyolysis, hepatitis, pancreatitis, thrombocytopenia or any liver related injury or liver damage.
Vytorin was approved by the FDA in 2004 in order to help reduce artery clogging plaque in patients with high cholesterol. A study found that Vytorin, a combination of cholesterol lowering Zetia and the statin Zocor, worked no better to reduce clogged arteries than a high dose of a less-expensive, generically available statin alone. It has, also, been more recently linked to an elevated risk of liver damage.
Vytorin is a combination of cholesterol lowering medication Zetia and the statin Zocor. The New York Times released an article that stated the manufacturers of Vytorin and Zetia conducted two studies that showed an elevated risk of developing liver damage, but they never published it. In January 2008, another study questioned the effectiveness of Vytorin because it showed no benefit to its users. Public Citizen released a report in December 2004 stating in part, “Indeed, there is already evidence from the FDA Adverse Events Reports System (AERS) that Zetia may, on its own, cause rhabdomyolysis, a serious and potentially fatal disease involving destruction or degeneration of skeletal muscle.” In January 2008, another study questioned the effectiveness of Vytorin because it showed no benefit to its users.
Rhabdomyolysis is the rapid breakdown of skeletal muscle tissue due to injury to muscle tissue. The destruction of the muscle leads to the release of the breakdown products of damaged muscle cells into the bloodstream, some of which is detrimental to the kidney and may lead to acute renal failure.
Side Effects of Vytorin
There are a variety of side effects associated with Vytorin. Our firm is pursing the following types of serious, life-threatening side effects:
- liver injury & liver damage